AstraZeneca CEO Pascal Soriot in recent interviews discussed the company’s recent moves as Brexit and EU customs talks continue, as well as his salary compared to his peers, according to a PMLiVE report.
Soriot in interviews with the Times and Sunday Times said the company had boosted its medicine stocks by some 20 percent, and “wasted” about $53 million on labs in Sweden to keep products on the market.
Failure to reach a deal on customs would be “really painful,” the executive said.
“I hope more and more people get worried,” he added.
Soriot also claims to be the lowest-paid CEO in the pharmaceutical industry, and that GlaxoSmithKline’s Emma Walmsley is also underpaid compared with their peers.
To read the full report on PMLiVE, click here.